The FDA is expected to make its decision on Priovant's application for brepocitinib in the third quarter. The company's rare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results